Human Papillomavirus (HPV) DNA Detection with Genotyping, High Risk Types by PCR [A Test in Focus]
By Andy Tofilon • February 11, 2014
This new Mayo Clinic assay detects the 14 high-risk HPV types, and if present, provides specific genotype results for HPV-16 and/or HPV-18. Together, HPV types 16 and 18 cause more than 60 percent of cervical cancer in the United States. View a three-minute video interview with Dr. Matt Binnicker, which provides greater detail about this assay.
This test may be ordered alongside cytology (i.e., co-testing) in women aged 30 to 65. In addition, this test may be used to assist in triaging women with abnormal (ASC-US) Pap smear results. Finally, the genotyping component of this test may be useful when co-testing reveals a positive result for high-risk HPV and normal cytology findings.
Up to 75% of women are exposed to human papilloma virus (HPV). Most infected women will clear the infection without any long-term health consequences.
Persistent HPV infection is the principal cause of cervical cancer and its precursor lesions (cervical intraepithelial neoplasia).
There are 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are classified as high-risk for the development of cervical cancer and its precursor lesions.
HPV types 16 and 18 cause >60% of cervical cancer.
Testing by PCR has become a standard method for determining the presence of a cervical HPV infection
The Mayo Clinic assay detects the 14 high-risk HPV types, and if present, provides specific genotype results for HPV-16 and/or HPV-18.
Real-Time Polymerase Chain Reaction (PCR) (PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Day(s) and Time(s) Test Performed: Monday through Friday; Varies
Analytic Time: 3 days
Andy Tofilon is a Marketing Segment Manager at Mayo Clinic Laboratories.